Physiological effects of parmodulins
| Parmodulin . | Experimental model . | Reference . |
|---|---|---|
| ML161 | In vitro: reduced thrombin generation and platelet adhesion on LPS or TNF-α stimulated EC | 41 |
| ML161, NRD-21 | In vitro: reduction of TF expression on TNF-α stimulated EC | 40 |
| ML161 | In vitro: prevention of thrombin, TNF-α or staurosporin-induced cell death | 45 |
| ML161 | In vitro: prevention of fXa-induced EMT of retinal pigment epithelial cells | 43 |
| ML161 | Microfluidic alveolar model: prevention of LPS-induced platelet accumulation on endothelial cells | 43 |
| JF5 | In vivo: laser-injury–induced thrombus formation (mouse) | 11 |
| ML161 | In vivo: laser-injury–induced thrombus formation (mouse) | 35 |
| ML161 | In vivo: reduced tissue injury and inflammation in myocardial IRI (mouse) | 49 |
| ML161 | In vivo: improvement of diabetic kidney disease by reducing glucose-induced and sustained tubular p21 expression | 50 |
| Parmodulin . | Experimental model . | Reference . |
|---|---|---|
| ML161 | In vitro: reduced thrombin generation and platelet adhesion on LPS or TNF-α stimulated EC | 41 |
| ML161, NRD-21 | In vitro: reduction of TF expression on TNF-α stimulated EC | 40 |
| ML161 | In vitro: prevention of thrombin, TNF-α or staurosporin-induced cell death | 45 |
| ML161 | In vitro: prevention of fXa-induced EMT of retinal pigment epithelial cells | 43 |
| ML161 | Microfluidic alveolar model: prevention of LPS-induced platelet accumulation on endothelial cells | 43 |
| JF5 | In vivo: laser-injury–induced thrombus formation (mouse) | 11 |
| ML161 | In vivo: laser-injury–induced thrombus formation (mouse) | 35 |
| ML161 | In vivo: reduced tissue injury and inflammation in myocardial IRI (mouse) | 49 |
| ML161 | In vivo: improvement of diabetic kidney disease by reducing glucose-induced and sustained tubular p21 expression | 50 |
EMT, epithelial-mesenchymal transition; IRI, ischemia reperfusion injury; TF, tissue factor.